January-July 2024,In ChinaTotal 1Six Antibody Drug-related Companies Complete Financing。From the perspective of financing rounds,From Angel Round to IPO, all are included.; In terms of the amount of financing,Ranging from tens of millions to hundreds of millionsThe following are the details of relevant companies and their financing. The main statistics focus on companies with antibody drug pipeline layouts. If there are any omissions, please feel free to leave a comment for supplementation.

1、Novamab

On July 31, Shanghai Novamab Biopharmaceuticals Co., Ltd. announced the completion of a nearly 200 million RMB B2 round of financing. This round was led by Qiming Venture Partners, with participation from Huangpu Biomedical Industry Fund and Jiuyu Investment. Existing shareholder Shengdi Investment continued to increase its investment.Notably, Novamab completed 7 rounds of financing within 5 years, with disclosed funding totaling over 400 million yuan, of which the B-round financing amounted to nearly 300 million yuan.

Novamab, established in 2017 and located in Zhangjiang, Shanghai, focuses on the research and development of inhalable nanobody drugs. It is currently the only company in China with full-process development capabilities for inhalable nanobodies. Its pipeline products, LQ036 and LQ043H, revolutionize the treatment of respiratory diseases and are both world-first inhalable nanobody drugs targeting the same respective sites.This round of fundraising is mainly used to promote thisThe clinical Phase II studies of two inhaled antibody drugs will simultaneously enrich the company's pipeline layout in the autoimmune field, enhance team capabilities, and further supplement corporate liquidity.

2. Wuxi Zhikang Hongyi Biotechnology Co., Ltd.

On July 31, Wuxi Zhikang Hongyi Biotechnology Co., Ltd. announced the completion of a multi-hundred million yuan A+ round of financing. This round of financing was led by Xichuang Investment and Binhu Industrial Group, with existing shareholders such as WuXi Biologics continuing to increase their investment.

Wuxi Zhikang Hongyi Biotechnology Co., Ltd. was founded in December 2017. As an innovation-driven biotechnology company, it focuses on the core mechanisms of disease occurrence, conducting in-depth research on the latest biological mechanisms in areas such as tumor signal transduction pathways and cellular immune responses. The company is actively building a leading translational medicine and clinical research business platform, prioritizing the discovery, development, clinical trials, and commercialization of "BIC/FIC" innovative drugs in the fields of oncology and chronic kidney disease. Among its core products, BC3195, a globally exclusive ADC drug targeting CDH3, is currently undergoing dose-expansion studies in multiple cohorts in Phase Ib clinical trials in both China and the United States.

3. Innovmab Therapeutics

July 23,Innovmab Therapeutics Completes Angel+ Round Financing from Dandelion (Shenzhen) Medical Venture Capital to Deeply Integrate Proteomics Technology Platform with Drug Development, Building Multiple ADC Pipelines with Best-in-Class Potential.

Innovmab Therapeutics is a company driven by omics big data to develop targeted drugs and novel precision medicine decision-making tools. Based on proteomics technology and a variety of highly clinically relevant disease model libraries such as PDX/PDO, the company has established a distinctive drug R&D decision-making tool platform. By utilizing highly clinically relevant big data and deep biological insights obtained through AI computation, it advances the high-success-rate development of its self-developed new drug pipelines and IVD products.Among them, inIn terms of drug development, the company currently owns multiple preclinical ADC new drug pipelines with innovative concepts, including products with unique targets based on more than 10 years of academic accumulation, which have the potential to become first-in-class products, giving the company a differentiated competitive advantage.

4. Baoji Pharmaceuticals

July 19,Shanghai Baoji Pharmaceuticals Announces Completion of CNY Hundreds of Millions in Series C Financing, Led by Shanghai BioPharmaceutical Fund, with Participation from Shanghai Sci-Tech Innovation Group, Baoshan State-Owned Investment Group, and Existing Shareholder Center Laboratories Limited.

Baoji Pharmaceuticals, established in December 2019, is a company in the field of synthetic biology and biopharmaceuticals that integrates drug research, development, production, and sales.Its core business is the industrialization and commercialization of recombinant protein drugs and antibody drugs. As the only biotechnology company in China specializing in recombinant enzyme medicines, enzyme delivery technologies, and combination therapies involving enzymes, antibodies, and gene therapy products, Baoji Pharmaceuticals has developed recombinant enzyme products and technologies that are mostly the first or exclusive in China.

5. Dasson Pharmaceuticals

On June 28, Dashi Pharmaceuticals (Guangdong) Co., Ltd. completed a new round of financing, with investors being Xiwan Investment Control and Guangdong Gaowei. However, the specific amount of financing was not disclosed.

DaiStone Pharma was founded in August 2017, with its headquarters located in Cuiheng New District, Zhongshan City, Guangdong Province, and its R&D center set up in Shanghai. It is an innovative antibody drug research and development enterprise focusing on pain management and complications from cancer treatment. The company has the first non-addictive analgesic antibody project in China and leading antibody engineering technology in China., itsThe core technology lies in antibody discovery, antibody molecular engineering modification, and the next-generation antibody humanization. Utilizing this technological platform, it extends to the development of antibody drugs in fields such as monoclonal antibody drugs, bispecific antibody drugs, and antibody-drug conjugates (ADC), demonstrating extremely high innovation and clinical application value.

6. Topthera Pharma

June 27,Top Chinese bispecific ADC company Tuoji Pharmaceuticals announces completion of a Pre-A round financing exceeding 100 million yuan, exclusively invested by Decheng Capital, with Index Capital serving as the exclusive financial advisor. Following this round of financing, Tuoji will increase R&D investment, accelerate the advancement of multiple preclinical pipelines, and upgrade its proprietary technology platform towards..."Accelerating towards the vision of becoming a global leading pharmaceutical company."

Torch Biopharmaceuticals was established in early 2022, firmly committed to the source innovation of ADC drugs. Its proprietary technology platform covers the four core technologies of ADC drugs (payload, linker, conjugation method, antibody), rapidly establishing advanced antibody discovery and bispecific antibody preparation platforms, a Linker-Payload design and synthesis platform, and a site-specific and stoichiometric conjugation technology platform.

7. Pulimab

On May 31, Fosun Pharma announced that its controlled enterprise Suzhou Xingweilai Fund, a third party Mangrove Investment, Puling Bio and its founding shareholders jointly signed the "A2 Round Investment Agreement". Suzhou Xingweilai Fund and Mangrove Investment plan to invest a total of RMB 16,833,333 in cash to subscribe for Puling Bio's additional registered capital totaling RMB 1,230,506.79.

Puling Bio was founded in July 2021 and is mainly engaged in the research and development of fourth-generation antibody-drug conjugates (ADC). Relying on its self-developed next-generation drug conjugation and delivery technology platform, it can screen for suitable linker-toxin systems targeting different antigens. The company primarily focuses on the development of traditional and novel ADC drug pipelines for cancer treatment (including nanobody ADCs, immuno-modulatory ADCs, and antibody-oligonucleotide conjugates AOC).

8. Shenghe Bio

On May 24, Shenghe Biotech successfully listed on the Main Board of the Hong Kong Stock Exchange, with the stock code 02898.HK.This global offering comprises approximately 34.15 million shares, priced at HKD 13.50 per share, raising a total of approximately HKD 461 million.

SinoHerc Bio was founded in 2018 as a biopharmaceutical company dedicated to the development of antibody cytokine products, focusing on the discovery, development, and commercialization of biologics for the treatment of cancer and autoimmune diseases. The company concentrates on innovative biologic drug research and development for cancer immunotherapy and autoimmune diseases by modulating the immune microenvironment.

The company currently has a total of 9 product pipelines., all of which are dual filings in China and the US. Among themThere are 3Both products are core products independently developed internally, and one of them isIt is an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) monoclonal antibody (mAb), indicated for colorectal cancer (CRC) and biliary tract cancer (BTC). The remaining two are antibody cytokines, indicated for advanced malignant solid tumors (including non-small cell lung cancer (NSCLC), non-muscle invasive bladder cancer (NMIBC), head and neck squamous cell carcinoma (HNSCC), and rectal cancer (CRC)), all of which are potentially first-in-class in the global market with rapid progress.

9. Quanxin Biologics

On March 20, Jiangsu Quanxin Biopharmaceutical Co., Ltd. officially went public on the Hong Kong stock market, becoming the "first HK-listed stock in autoimmune diseases."This global offering comprises 12,046,400 H shares, with each lot consisting of 200 shares. The issue price is HKD 19.80 per share, raising approximately HKD 239 million.

Quanxin Biologics, established in 2015, is a clinical-stage innovative company focused on biologic therapies for autoimmune and allergic diseases. It has a fully self-developed drug pipeline and mature commercial-scale internal production capabilities. Currently, Quanxin Biologics has built a comprehensive product pipeline covering four major disease areas—skin, rheumatology, respiratory, and gastrointestinal diseases—in the autoimmune and allergic chronic disease fields. This pipeline includes nine candidate drugs, six of which are in clinical stages.

10. Kerun Bio

News on March 5: KERUN Biotech Completes Tens of Millions of Yuan in Series A+ Financing. This round of financing was led by Zhirui Investment, and the funds raised will be mainly used for clinical research of KERUN Biotech's ophthalmology and oncology pipeline products, promoting the rapid industrialization and commercialization of the company’s products. According to KERUN Biotech's press release, the company has completed over 100 million yuan in financing in the past two years.

Kerun Biotech was founded in 2005 and focuses on the development of recombinant protein drugs. The company's product pipeline is centered on the research and development of biologic macromolecular drugs in ophthalmology and oncology. In the field of anti-cancer drug development, Kerun Biotech has developed a Class 1 new drug, recombinant carboxypeptidase G2 for injection, and is currently developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies such as leukemia and lymphoma, having completed proof-of-concept work for multiple molecules.

11. Shuoxing Bio

February 28Beijing Novamab Biopharmaceuticals Co., Ltd. announced the completion of a multi-million yuan A+ round of financing. This round of financing was jointly invested by Zhuhai Science and Technology Investment, Zhuhai High-Tech Investment, and Guangda Huitong, with Qidian Capital serving as the financial advisor for subsequent rounds of financing. In fact, prior to this round of financing, Novamab had already gained favor from investment institutions such as Aethan Capital, CICC Capital, Huajin Capital, and Chang'an Private Capital.

Stellar Biologics was founded in 2019. Based on its proprietary nano-multi-antibody biologics platform technology, the company focuses on addressing indications currently lacking treatment options, and is committed to developing innovative multi-functional antibody drugs as well as their clinical research and commercialization worldwide. The company has established a pipeline of approximately 10 products under development, covering oncology, inflammation, ophthalmology, and neurological diseases. Among them, SM3321, a nano-multi-antibody drug targeting dual tumor targets and CD16A agonist-mediated pathways, is one of the more advanced candidates. It has already received IND approval in both China and the United States and has entered Phase I clinical trials.

12. Simcere Zaiming

On February 24, Simcere Pharmaceutical announced that its subsidiary, Simcere Zaiming, had completed a financing round of 970 million yuan. The company's pre-money valuation was 7.5 billion yuan, with a post-money valuation of 8.47 billion yuan. SDIC Capital (Advanced Manufacturing) led the investment with 800 million yuan, while Zhongshen Xinchuang invested 100 million yuan, Apricot Field Capital invested 50 million yuan, and Zhonghe Capital invested 20 million yuan.

Simcere Zaiming is a biopharmaceutical company under Simcere Pharmaceutical Group, focused on the research, development, production, and commercialization of innovative anti-cancer drugs. Established in December 2020, it began independent operations in 2023. The company is committed to addressing significant unmet clinical needs in oncology in China and globally through breakthrough therapies. It possesses several core technology platforms, including a protein engineering platform, multi-antibody/TCE platform, multi-antibody/NKCE platform, and an AI-assisted molecular generation platform.The R&D mainly focuses on core areas such as lung cancer, gastrointestinal tumors, and gynecological tumors, with a particular emphasis on mechanisms like tumor immunity, cancer driver genes, and synthetic lethality.

13. Pufang Bio

February 16,Profound Bio Announces $112 Million Oversubscribed Series B Financing to Accelerate Development of Its Antibody-Drug Conjugate (ADC) Pipeline, Including Advancing Key Clinical Trials for ADC Product Rinatabart Sesutecan (Rina-S) for the Treatment of Ovarian Cancer.It is reported that theThis round of financing was led by Ally Bridge Group, with other follow-up investors including Nextech Invest, T. Rowe Price Associates, and Janus Henderson Investors.etc.

ProfoundBio Focuses on Developing Next-Generation Macromolecular Targeted Anticancer Drugs, with a Product Pipeline Mainly Including ADC and Other Antibody-Based Therapeutic Solutions. Notably, on April 3, Genmab and ProfoundBio announced that the two companies had reached a definitive agreement under which Genmab will acquire ProfoundBio for $1.8 billion in cash, payable upon closing (subject to adjustments based on ProfoundBio's net debt and transaction expenses at the end of the period).

14. I-Mab Biopharma

February 7,Tianjing Biotechnology (Hangzhou) Co., Ltd. announced that it has reached an agreement with Nasdaq-listed I-Mab to integrate and restructure all of I-Mab's China operations, teams, and pipeline with the company’s existing pipeline and assets. At the same time, the company also announced the completion of a C1 round of financing exceeding 500 million RMB. This round of financing was jointly invested by Tylon Investment, Zhejiang Province's "4+1" Healthcare Fund, I-Mab, Hangzhou Qiantang New City Development Technology Service Co., Ltd., Bruggemoon Limited, and Ningbo KaiTou Hanrun Capital. Heryue Capital served as the exclusive financial advisor for this transaction.

I-MabFounded in June 2019, the company aims to build a leading biopharmaceutical company in China that integrates R&D, production, licensing, and product sales, and has established teams for large-molecule antibody drug discovery, pharmaceutical process development, technology transfer, manufacturing, preclinical research, and clinical research.CompanyThe integrated innovative drug pipeline includes 10 clinical-stage projects and 7 innovative drug projects in the preclinical or clinical application stage.

15. Nuoling Bio

On January 8, Novamab completed its B1 financing round.This round of financing was led by the Taikun Fund under Tylon Investment, with some existing shareholders following suit. The funds from this round will primarily support the clinical development of NC18 and accelerate other ADC products in the pipeline towards IND.

Novamab was founded in October 2015 by Dr. Wang Yang and Dr. Sun Binyuan, who have long been dedicated to utilizing original and highly differentiated innovative technology platforms to develop conjugated drugs targeting unmet clinical needs. The company has independently developed two major ADC platforms with proprietary intellectual property rights for polymer conjugation and small molecule conjugation, enabling optimal screening of various ADCs with different conjugation methods and cytotoxins. These platforms have the potential to address current pain points in ADC development, such as narrow therapeutic windows and significant side effects caused by low DAR and high shedding rates. Through a combination of in-house R&D and collaboration, Novamab has multiple BIC/FIC novel ADCs currently under development.

16. Angkuo Pharmaceuticals

On January 4, Oncure Medicine announced the completion of an oversubscribed $100 million (over 700 million RMB) Series A financing round. This round was led by Novo Holdings, OrbiMed, and F-Prime Capital from the United States, with participation from Sofinnova Investments, Catalio Capital Management, Marshall Wace, Forge Life Science Partners, Blackbird BioVentures, CJNV BioVentures, and Boyuan Capital, where Boyuan Capital was one of the co-leading investors in the seed round.

OnQuality Pharmaceuticals is a global biopharmaceutical company dedicated to transforming cutting-edge oncology drugs into innovative therapies. It was co-founded by Dr. Yuan Bin, Dr. Eric Slosberg, and Dr. Fu Tian in April 2021. Since its establishment, OnQuality Pharmaceuticals has raised $139 million (approximately 1 billion RMB). The proceeds from this financing will be used to advance the clinical development of the company's CUSP06 project, an antibody-drug conjugate (ADC) targeting CDH6. Additionally, the funds will support the expansion of the company’s product pipeline and team.

Scan the WeChat QR code to add.Medicine Space-TimeEditor

Please indicate: Name + Research Direction!